20 LATEST RESOURCES (30 INDEXED)
Levomilnacipran for Negative Symptom Domain Schizophrenia · December 2021
Articles
Primary Care Companion for CNS Disorders
Cost-Effectiveness of Vortioxetine Compared with Levomilnacipran and Vilazodone in Patients with Major Depressive Disorder Switching from an Initial Antidepressant · January 2021
Abstracts
Expert Review of Pharmacoeconomics and Outcomes Research
Relapse Prevention with Levomilnacipran ER in Adults with Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study · January 2019
Articles
Depression and Anxiety
The Role of New Antidepressants in Clinical Practice in Canada: A Brief Review of Vortioxetine, Levomilnacipran ER, and Vilazodone · November 2017
Articles
Neuropsychiatric Disease and Treatment
Efficacy and Safety of Levomilnacipran, Vilazodone and Vortioxetine Compared with Other Second-Generation Antidepressants for Major Depressive Disorder in Adults: A Systematic Review and Network Meta-Analysis · November 2017
Abstracts
Journal of Affective Disorders
Measures of Suicidality in Phase 3 Clinical Trials of Levomilnacipran ER in Adults with Major Depressive Disorder · May 2017
Articles
CNS Spectrums
Effects of Levomilnacipran Extended-Release on Major Depressive Disorder Patients with Cognitive Impairments: Post-Hoc Analysis of a Phase III Study · March 2017
Articles
International Clinical Psychopharmacology
Effects of Levomilnacipran ER on Noradrenergic Symptoms, Anxiety Symptoms, and Functional Impairment in Adults with Major Depressive Disorder: Post Hoc Analysis of 5 Clinical Trials · November 2016
Articles
Journal of Affective Disorders
Effects of Levomilnacipran Extended-Release on Motivation/Energy and Functioning in Adults with Major Depressive Disorder · November 2016
Articles
International Clinical Psychopharmacology
Efficacy and Safety of Multiple Doses of Levomilnacipran Extended-Release for the Treatment of Major Depressive Disorder · October 2016
Articles
Neuropsychiatric Disease and Treatment
The Efficacy of Levomilnacipran ER Across Symptoms of Major Depressive Disorder: A Post Hoc Analysis of 5 Randomized, Double-Blind, Placebo-Controlled Trials · June 2016
Articles
CNS Spectrums
Effects of Levomilnacipran ER on Fatigue Symptoms Associated with Major Depressive Disorder · March 2016
Articles
International Clinical Psychopharmacology
The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review · February 2016
Articles
NCBI>Current Neuropharmacology
Vortioxetine for Major Depressive Disorder: An Indirect Comparison with Duloxetine, Escitalopram, Levomilnacipran, Sertraline, Venlafaxine, and Vilazodone, Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed · February 2016
Abstracts
Journal of Affective Disorders
The Effects of Levomilnacipran ER in Adult Patients with First-Episode, Highly Recurrent, or Chronic MDD · December 2015
Articles
Journal of Affective Disorders
Levomilnacipran Extended-Release Treatment in Patients with Major Depressive Disorder: Improvements in Functional Impairment Categories · June 2015
Articles
Primary Care Companion for CNS Disorders
Levomilnacipran and Vortioxetine: Review of New Pharmacotherapies for Major Depressive Disorder · March 2015
Articles
World Journal of Pharmacology
Prescriber’s Guide to Using 3 New Antidepressants: Vilazodone, Levomilnacipran, Vortioxetine · February 2015
Articles
Current Psychiatry
Levomilnacipran for the Treatment of Major Depressive Disorder: A Review · January 2015
Articles
Neuropsychiatric Disease and Treatment
A Review of the Clinical Efficacy, Safety and Tolerability of the Antidepressants Vilazodone, Levomilnacipran and Vortioxetine · September 2014
Abstracts
Expert Opinion on Pharmacotherapy